Copyright
©The Author(s) 2018.
World J Clin Oncol. Sep 14, 2018; 9(5): 110-118
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Figure 1 Comparison of the FOLFIRI-1and FOLFIRI-3 schedules.
Figure 2 Flow diagram.
Figure 3 Progression-free survival and overall survival according to prior exposure to irinotecan (n = 65).
A: Progression-free survival; B: Overall survival.
- Citation: Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118
- URL: https://www.wjgnet.com/2218-4333/full/v9/i5/110.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i5.110